Literature DB >> 24164237

Dr. Sonia Skarlatos and the National Heart, Lung, and Blood institute translational research and resource programs.

Cheryl L McDonald1.   

Abstract

Sonia I. Skarlatos, PhD (September 28, 1953-August 6, 2013), was the deputy director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI). This article reviews her work in establishing, leading, or facilitating extramural translational research programs supported by the NHLBI, specifically focusing on her work as a consistent advocate for the advancement of gene and cell therapies.

Mesh：

Year:  2013        PMID： 24164237      PMCID： PMC3815047          DOI： 10.1089/hum.2013.2511

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


  16 in total

Review 1.  Support for cardiovascular cell therapy research at the National Heart, Lung, and Blood Institute.

Authors:  Denis B Buxton; Sonia I Skarlatos
Journal:  Circ Res       Date:  2012-06-08       Impact factor: 17.367

Review 2.  Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community.

Authors:  Michael S Lauer; Sonia Skarlatos
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 3.  New programs for gene- and cell-based therapies at NHLBI.

Authors:  S I Skarlatos
Journal:  Clin Pharmacol Ther       Date:  2007-07-11       Impact factor: 6.875

Review 4.  Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP).

Authors:  Cheryl L McDonald; Janet Benson; Kenneth Cornetta; Margaret Diggins; Julie C Johnston; Susan Sepelak; Gensheng Wang; James M Wilson; J Fraser Wright; Sonia I Skarlatos
Journal:  Hum Gene Ther Clin Dev       Date:  2013-04-03       Impact factor: 5.032

5.  Research agenda. Opportunities for research and NIH.

Authors:  Francis S Collins
Journal:  Science       Date:  2010-01-01       Impact factor: 47.728

6.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

7.  Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).

Authors:  Robert D Simari; Lemuel A Moyé; Sonia I Skarlatos; Stephen G Ellis; David X M Zhao; James T Willerson; Timothy D Henry; Carl J Pepine
Journal:  J Cardiovasc Transl Res       Date:  2010-02       Impact factor: 4.132

8.  Oversight and management of a cell therapy clinical trial network: experience and lessons learned.

Authors:  Lemuel A Moyé; Shelly L Sayre; Lynette Westbrook; Beth C Jorgenson; Eileen Handberg; Saif Anwaruddin; Kristi A Wagner; Sonia I Skarlatos
Journal:  Contemp Clin Trials       Date:  2011-05-17       Impact factor: 2.226

9.  Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Authors:  Jay H Traverse; Timothy D Henry; Stephen G Ellis; Carl J Pepine; James T Willerson; David X M Zhao; John R Forder; Barry J Byrne; Antonis K Hatzopoulos; Marc S Penn; Emerson C Perin; Kenneth W Baran; Jeffrey Chambers; Charles Lambert; Ganesh Raveendran; Daniel I Simon; Douglas E Vaughan; Lara M Simpson; Adrian P Gee; Doris A Taylor; Christopher R Cogle; James D Thomas; Guilherme V Silva; Beth C Jorgenson; Rachel E Olson; Sherry Bowman; Judy Francescon; Carrie Geither; Eileen Handberg; Deirdre X Smith; Sarah Baraniuk; Linda B Piller; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2011-11-14       Impact factor: 56.272

10.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728
View more
  1 in total

1.  Dr. Sonia Skarlatos-leader, colleague, and friend: from vascular biology to gene therapy and the Cardiovascular Cell Therapy research network.

Authors:  Keith L March
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.